Laboratory Services

KRAS Mutation Analysis

Print this page

Updated Test Information:

Test Description
KRAS Mutation Analysis

KRAS, K-RAS, RAS, KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation)

Test ID


General Information

Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing is available separately or in combination with BRAF, HRAS and NRAS in the RAS/RAF Panel.

KRAS testing in non-small cell lung cancer may provide prognostic information, predict poor response to EGFR tyrosine kinase inhibitors, and inform on possible response to targeted therapy such as sotorasib. 

Specimen Type

FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Required Information

Complete the Incyte Diagnostics requisition with the patient's demographics, ordering physician, and a copy of the pathology report.


Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

Department (code)

Molecular Pathology

Estimated TAT

8 Days


Extracted DNA is kept for 30 days.

CPT Code(s)


Performing Lab

NeoGenomics Laboratories